Kairos Pharma, LTD.
kairospharma.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Kairos Pharma shows significant deterioration with 31% increase in quarterly losses, declining cash position from $4.5M to $3.7M, and material weaknesses in internal controls remaining unresolved. The company operates as a pre-revenue biotech with accelerating burn rate and inadequate financial controls.
Red Flags Detected (6)
Net loss increased 31% from $1.262M to $1.654M quarter-over-quarter
Cash declined $816k (18%) from December to March 2026
Material weakness in internal controls persists - inadequate segregation of duties and review procedures
3 more red flags detected
Key Takeaways
Company raised only $367k through ATM offering in Q1 2026, indicating limited market appetite
Current cash runway appears insufficient given $1.7M quarterly burn rate
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.